Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade
Posted innews Oncology Respiratory

Durable Survival and Enhanced Downstaging: Long-term Insights from the NEOpredict-Lung Trial on Preoperative PD-1 and LAG-3 Blockade

Extended follow-up of the NEOpredict-Lung trial demonstrates that short-course preoperative nivolumab, with or without relatlimab, yields high 3-year survival rates and significant nodal downstaging in resectable NSCLC, positioning dual checkpoint inhibition as a potent chemotherapy-free neoadjuvant alternative.
Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial
Posted innews Oncology Radiology

Tumor Treating Fields Significantly Delay Intracranial Progression in NSCLC Patients Following Stereotactic Radiosurgery: Results of the METIS Trial

The Phase 3 METIS trial demonstrates that Tumor Treating Fields (TTFields) following stereotactic radiosurgery significantly prolongs time to intracranial progression in NSCLC patients with brain metastases, without compromising neurocognitive function or quality of life, offering a promising new treatment paradigm.
Prostate Cancer Statistics 2025: The Resurgence of Advanced Disease and Persistent Racial Disparities
Posted inClinical Updates news Oncology

Prostate Cancer Statistics 2025: The Resurgence of Advanced Disease and Persistent Racial Disparities

This review analyzes 2025 prostate cancer data, highlighting a 3% annual incidence increase primarily driven by advanced-stage disease. It explores age-specific trends, significant racial inequities in mortality, and the clinical challenges of optimizing early detection while managing advanced disease complications.
Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial
Posted innews Oncology Otorhinolaryngology

Proton Therapy Outperforms Photons in Oropharyngeal Cancer: Superior Survival and Reduced Toxicity in a Phase 3 Trial

A landmark Phase 3 trial establishes Intensity-Modulated Proton Therapy (IMPT) as a new standard for oropharyngeal cancer, demonstrating non-inferior progression-free survival, significantly improved overall survival, and a marked reduction in long-term toxicities such as gastrostomy tube dependence.
Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC
Posted innews Oncology Radiology

Bevacizumab and Fractionated Stereotactic Radiotherapy: A Synergistic Breakthrough for Extensive Brain Metastases in NSCLC

The GASTO-1053 phase II study demonstrates that combining bevacizumab with fractionated stereotactic radiotherapy significantly improves intracranial progression-free survival (18.3 months) and quality of life for NSCLC patients with extensive brain metastases, providing a safe, effective alternative to whole-brain radiotherapy.
Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial
Posted inGastroenterology news Oncology

Adjuvant Camrelizumab plus Capecitabine Extends Recurrence-Free Survival in Resected Intrahepatic Cholangiocarcinoma: Results from the Phase 2 ACC Trial

The Phase 2 ACC trial demonstrates that adjuvant camrelizumab combined with capecitabine achieves a median recurrence-free survival of 24.29 months for patients with resected intrahepatic cholangiocarcinoma, offering a promising and manageable immunochemotherapy strategy for this high-risk population.